Published Jul 22, 2024

FDA Panel Rejects MDMA Therapy For PTSD

Explore the complexities behind the FDA's rejection of MDMA therapy for PTSD as experts delve into trial participants' motivations, challenges in psychedelic research, and the methodological flaws that hinder future advancements in psychotherapy.

Episode Highlights

Topics covered

Popular Clips

Episode Highlights

Related Episodes

The Bumpy Road To Approving New Alzheimer’s Drugs
Answers 383 questions
FDA Approves A New, Non-Opioid Painkiller | Deep, Multi-Layer Oceans On Uranus And Neptune?
Answers 383 questions
How Magnetic Brain Stimulation Helps Relieve Depression
Answers 383 questions
The FDA Approved The First CRISPR-Based Therapy. What’s Next?
Answers 383 questions
Improving Hospitals’ Support For Teens In Mental Health Crises
Answers 383 questions
NASA Opens Canister With Asteroid Sample | ADHD Prescription Rates Spiked During The Pandemic
Answers 383 questions
Surgeon General Takes On Parental Stress And Mental Health
Answers 383 questions
Why Are There So Many Drug Shortages In The U.S.?
Answers 383 questions
A Young Scientist Uplifts The Needs Of Parkinson’s Patients
Answers 383 questions
Dr. Fauci On A Life Of Medical Research And Public Service
Answers 383 questions
CAR-T Cell Therapy For Autoimmune Diseases | Measuring Early Life Adversity—In Marmots
Answers 383 questions
Science Unlocks The Power Of Flavor In ‘Flavorama’
Answers 383 questions
Could Light And Sound Therapy Treat Alzheimer’s?
Answers 383 questions
When Products Collect Data From Your Brain, Where Does It Go?
Answers 383 questions
Challenging The Gender Gap In Sports Science
Answers 383 questions

Dexa/Science Friday

FDA Panel Rejects MDMA Therapy For PTSD

Topics covered

Popular Clips

Study Methodology Concerns

MDMA and Psychotherapy

MDMA Therapy Insights

Precision in Psychotherapy

Trial Complexities

MDMA Therapy Insights

MDMA Therapy Challenges

Episode Highlights

Participant Perspectives

Future Directions in MDMA Research

MDMA Therapy Challenges

Related Episodes

The Bumpy Road To Approving New Alzheimer’s Drugs

FDA Approves A New, Non-Opioid Painkiller | Deep, Multi-Layer Oceans On Uranus And Neptune?

How Magnetic Brain Stimulation Helps Relieve Depression

The FDA Approved The First CRISPR-Based Therapy. What’s Next?

Improving Hospitals’ Support For Teens In Mental Health Crises

NASA Opens Canister With Asteroid Sample | ADHD Prescription Rates Spiked During The Pandemic

Surgeon General Takes On Parental Stress And Mental Health

Why Are There So Many Drug Shortages In The U.S.?

A Young Scientist Uplifts The Needs Of Parkinson’s Patients

Dr. Fauci On A Life Of Medical Research And Public Service

CAR-T Cell Therapy For Autoimmune Diseases | Measuring Early Life Adversity—In Marmots

Science Unlocks The Power Of Flavor In ‘Flavorama’

Could Light And Sound Therapy Treat Alzheimer’s?

When Products Collect Data From Your Brain, Where Does It Go?

Challenging The Gender Gap In Sports Science

FDA Panel Rejects MDMA Therapy For PTSD

Topics covered

Popular Clips

Episode Highlights

Participant PerspectivesThe discussion explores the motivations behind participating in MDMA therapy trials and the trust issues surrounding psychedelic research. Sarah McNamee shares her personal journey and concerns about the reliability of current studies.

Participant Perspectives

Future Directions in MDMA ResearchThe FDA's rejection of MDMA therapy for PTSD underscores the need for improved study designs and precision in psychotherapy. Eiko Fried and Sarah McNamee discuss how these factors could enhance the validity and effectiveness of future trials.

Future Directions in MDMA Research

MDMA Therapy ChallengesThe FDA's decision to reject MDMA therapy for PTSD was influenced by significant methodological flaws in the clinical trials. Eiko Fried and Sarah McNamee discuss the challenges and biases that undermined the study's reliability.

MDMA Therapy Challenges

Related Episodes